Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. Chemotherapy. Hormone. Weill Cornell Medical College, New York, NY, United States



Survival: 48.0 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
Hormone
   
Drugs: Adriamycin
Country: United States
   
City/State/Province: New York, NY
   
Hospital: Weill Cornell Medical College
   
Journal: Link
   
Date: 4/2014

Description:
Patients:
This phase 2 study involved 11 mantle cell lymphoma patients who had not been previously treated. The median patient age was 60 years and 8 were men.

Treatment:
Patients were treated with the biologic therapy agent bevacizumab and a treatment regimen called R-CHOP that consists of rituximab (biologic) cyclophosphamide, adriamycin, vincristine (chemotherapy), and prednisone (hormone).

Toxicities:
The most severe toxicities were of grade 4 and included grade 3-4 anemia, neutropenia, and heart dysfunction.

Results:
The median overall survival was 48 months.

Support:
One of the authors has received funding from Genentech and Biogen Idec.

Correspondence: Dr. John P. Leonard; email: jpleonar@med.cornell.edu

E-mail to a Friend Email Physician More Information